Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 01
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
NovoCure Ltd
NVCR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$15.92
-0.03
-0.19%
Últ. Act.: Oct 1, 4:02 PM
$16.36
0.41
2.57%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
NovoCure Financials
NovoCure (NVCR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
Akanksha Bakshi
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights
PRO
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est
NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.000 million-$725.000 million vs $708.743 million estimate.
Benzinga Newsdesk
PRO
NovoCure Q2 EPS $(0.13) Beats $(0.33) Estimate, Sales $183.584M Beat $172.437M Estimate
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.33) by 60.61 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the
Benzinga Newsdesk
PRO
NovoCure Raises FY2026 Sales Guidance from $675.000M-$705.000M to $690.000M-$710.000M vs $692.115M Est
NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $675.000 million-$705.000 million to $690.000 million-$710.000 million vs $692.115 million estimate.
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
